Conventional external-beam radiation therapy alone or with androgen ablation for clinical stage III (T3, NX/N0, M0) adenocarcinoma of the prostate

International Journal of Radiation Oncology Biology Physics

Volumn 44, Issue 4, 1999, Pages 809-819

  Zagars, Gunar K ^a   Pollack, Alan ^a   Smith, Lewis G ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

Androgen ablation; Dose response; Prostate cancer; Radiation therapy

Indexed keywords

ANDROGEN; PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER STAGING; CONTROLLED STUDY; DOSE RESPONSE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE ADENOCARCINOMA; RADIATION DOSE;

ACID PHOSPHATASE; ADENOCARCINOMA; AGED; ANALYSIS OF VARIANCE; ANDROGEN ANTAGONISTS; ANTINEOPLASTIC AGENTS, HORMONAL; COHORT STUDIES; COMBINED MODALITY THERAPY; FOLLOW-UP STUDIES; GONADOTROPIN-RELEASING HORMONE; HUMANS; MALE; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; ORCHIECTOMY; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RADIOTHERAPY, CONFORMAL;

EID: 0033054069     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0360-3016(99)00089-9     Document Type: Article

References (49)

1. Bagshaw M.A., Cox R.S., Hancock S.L. Control of prostate cancer with radiotherapy: Long-term results. J Urol. 152:1994;1781-1785.
2. Zagars G.K., von Eschenbach A.C., Johnson D.E., et al. Stage C adenocarcinoma of the prostate. Analysis of 551 patients treated with external beam radiation therapy. Cancer. 60:1987;1489-1499.
3. Whitmore W.F. Hormone therapy in prostate cancer. Am J Med. 21:1956;697-713.
4. American Joint Committee on Cancer. AJCC cancer staging manual. 5th ed. Philadelphia: Lippincott-Raven; 1997. p. 219-224.
5. Zagars G.K., von Eschenbach A.C., Ayala A.G. Prognostic factors in prostate cancer. Analysis of 874 patients treated with radiation therapy. Cancer. 72:1993;1709-1725.
6. Amdur R.J., Parsons J.T., Fitzgerald L.T., et al. Adenocarcinoma of the prostate treated with external-beam radiation therapy: 5-year minimum follow-up. Radiother Oncol. 18:1990;235-246.
7. Perez C.A. Carcinoma of the prostate: A model for management under impending health care system reform. Radiology. 196:1995;309-322.
8. Hanks G.E. External-beam radiation therapy for clinically localized prostate cancer: Patterns of care studies in the United States. NCI Monogr. 7:1988;75-84.
9. Bagshaw M.A., Cox R.S., Ray G.R. Status of radiation treatment of prostate cancer at Stanford University. NCI Monogr. 7:1988;40-60.
10. Zagars G.K., von Eschenbach A.C. Prostate-specific antigen: An important marker for prostate cancer treated by external beam radiation therapy. Cancer. 72:1993;538-548.
11. Schellhammer P.F., El-Mahdi A.M., Wright G.L., et al. Prostate-specific antigen to determine progression-free survival after radiation therapy for localized carcinoma of prostate. Urology. 42:1993;13-20.
12. Zagars G.K., Pollack A., von Eschenbach A.C. Prognostic factors in clinically localized prostate cancer. Analysis of 938 patients irradiated in the PSA era. Cancer. 79:1997;1370-1380.
13. Kaplan I.D., Cox R.S., Bagshaw M.A. Prostate specific antigen after external beam radiotherapy for prostate cancer: Follow-up. J Urol. 149:1993;519-522.
14. Zietman A.L., Coen J.J., Shipley W.U., et al. Radical radiation therapy in the management of prostatic adenocarcinoma: The initial prostate specific antigen value as a predictor of treatment outcome. J Urol. 151:1994;640-645.
15. Pisansky T.M., Cha S.S., Earle J.D., et al. Prostate-specific antigen as a pretherapy prognostic factor in patients treated with radiation therapy for clinically localized prostate cancer. J Clin Oncol. 11:1993;2158-2166.
16. Pisansky T.M., Kahn M.J., Rasp G.M., et al. A multiple prognostic index predictive of disease outcome after irradiation for clinically localized prostate carcinoma. Cancer. 79:1997;337-344.
17. Movsas B., Hanlon A.L., Teshima T., et al. Analyzing predictive models following definitive radiotherapy for prostate carcinoma. Cancer. 1997;1093-1102.
18. Zietman A.L., Westgeest J.C.M., Shipley W.U. Radiation-based approaches to the management of T3 prostate cancer. Semin Urol Oncol. 15:1997;230-238.
19. Zelefsky M.J., Leibel S.A., Gaudin P.B., et al. Dose escalation with three-dimensional conformal radiation therapy affects the outcome in prostate cancer. Int J Radiat Oncol Biol Phys. 41:1998;491-500.
20. Hanks G.E., Hanlon A.L., Schultheiss T.E., et al. Dose escalation with 3D conformal treatment: Five year outcomes, treatment optimization, and future directions. Int J Radiat Oncol Biol Phys. 41:1998;501-510.
21. Pollack A., Zagars G.K., Starkschall G., et al. Conventional versus conformal radiotherapy for prostate cancer: Preliminary results of dosimetry and acute toxicity. Int J Radiat Oncol Biol Phys. 34:1996;555-564.
22. Zagars G.K., Geara F.B., Pollack A., et al. The T classification of clinically localized prostate cancer. An appraisal based on disease outcome following radiation therapy. Cancer. 73:1994;1904-1912.
23. Zagars G.K., Ayala A.G., von Eschenbach A.C., et al. The prognostic significance of Gleason grade in prostatic adenocarcinoma: A long-term follow-up study of 648 patients treated with radiation therapy. Int J Radiat Oncol Biol Phys. 31:1995;237-245.
24. Roy A.V., Bower M.E., Hayden J.E. Sodium thymolphthalein monophosphate: A new acid phosphatase substrate with greater specificity for the prostatic enzyme in serum. Clin Chem. 17:1971;1093-1102.
25. Zagars G.K. Prostate-specific antigen as a prognostic factor for prostate cancer treated by external beam radiotherapy. Int J Radiat Oncol Biol Phys. 23:1992;47-53.
26. Pollack A., Zagars G.K. External beam radiotherapy dose-response of prostate cancer. Int J Radiat Oncol Biol Phys. 39:1997;1011-1018.
27. Zagars G.K., Pollack A., von Eschenbach A.C. Management of unfavorable locoregional prostate carcinoma with radiation and androgen ablation. Cancer. 80:1997;764-775.
28. Consensus statement: Guidelines for PSA following radiation therapy. Int J Radiat Oncol Biol Phys. 37:1997;1035-1041.
29. Ciampi A., Chang C.H., Hogg S., et al. Recursive partition: A versatile method for exploratory data analysis. McNeil I.B., Umphrey G.J. Biostatistics. 1987;23-50 Reidel, New York.
30. Venables WN, Ripley BD. Modern applied statistics with S-Plus. New York: Springer; 1997. p. 413-30.
31. Harris EK, Albert A. Survivorship analysis for clinical studies. New York: Dekker; 1991. p. 5-125.
32. Rothman K.J. Estimation of confidence limits for the cumulative probability of survival in life table analysis. J Chron Dis. 31:1978;557-560.
33. U.S. Department of Health, Education, and Welfare: Vital Statistics of the United States, 1988. Hyattsville, MD: Public Health Service National Center for Health Statistics.
34. Partin A.W., Pound C.R., Clemens J.Q., et al. Serum PSA after anatomic radical prostatectomy. The Johns Hopkins experience after 10 years. Urol Clin North Am. 20:1993;713-725.
35. Zagars G.K., Pollack A., von Eschenbach A.C. Prostate cancer and radiation therapy - the message conveyed by serum prostate-specific antigen. Int J Radiat Oncol Biol Phys. 33:1995;23-35.
36. Shipley W.U., Verhey L.J., Munzenrider J.E., et al. Advanced prostate cancer: The results of a randomized comparative trial of high dose irradiation boosting with conformal protons compared with conventional dose irradiation using photons alone. Int J Radiat Oncol Biol Phys. 32:1995;3-12.
37. Hanks G.E. Optimizing the radiation treatment and outcome of prostate cancer. Int J Radiat Oncol Biol Phys. 11:1985;1235-1245.
38. Perez C.A., Walz B.J., Zivnuska F.R., et al. Irradiation of carcinoma of the prostate localized to the pelvis: Analysis of tumor response and prognosis. Int J Radiat Oncol Biol Phys. 6:1980;555-563.
39. Bagshaw M.A., Cox R.S., Ray G.R. Status of radiation treatment of prostate cancer at Stanford University. NCI Monogr. 7:1988;47-60.
40. Nguyen L.N., Pollack A., Zagars G.K. Late effects after radiotherapy for prostate cancer in a randomized dose-response study: Results of a self-assessment questionnaire. Urology. 51:1998;991-997.
41. Pilepich M.V., Caplan R., Byhardt R.W., et al. Phase III trial of androgen suppression using goserelin in unfavorable-prognosis carcinoma of the prostate treated with definitive radiotherapy: Report of Radiation Therapy Oncology Group Protocol 85-31. J Clin Oncol. 15:1997;1013-1021.
42. Bolla M., Gonzalez D., Warde P., et al. Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin. N Engl J Med. 337:1997;295-300.
43. Pilepich M.V., Krall J.M., Al-Sarraf M., et al. Androgen deprivation with radiation therapy compared with radiation therapy alone for locally advanced prostatic carcinoma: A randomized comparative trial of the Radiation Therapy Oncology Group. Urology. 45:1995;616-623.
44. Zagars G.K., Johnson D.E., von Eschenbach A.C., et al. Adjuvant estrogen following radiation therapy for stage C adenocarcinoma of the prostate. Long-term results of a prospective randomized study. Int J Radiat Oncol Biol Phys. 14:1988;1085-1091.
45. Laverdiere J., Gomez J.L., Cusan L., et al. Beneficial effect of combination hormonal therapy administered prior and following external beam radiation therapy in localized prostate cancer. Int J Radiat Oncol Biol Phys. 37:1997;247-252.
46. Denis L.J., Whelan P., DeMoura J.L., et al. Goserelin acetate and flutamide versus bilateral orchiectomy. A phase II EORTC trial (30853). Urology. 42:1993;119-130.
47. Crawford E.D., Eisengerger M.A., McLeod D.G., et al. A controlled trial of leuprolide with and without flutamide in prostate carcinoma. N Engl J Med. 321:1989;419-424.
48. Maximum androgen blockade in advanced prostate cancer: An overview of 22 randomized trials with 3283 deaths in 5710 patients. Lancet. 346:1995;265-269.
49. Gleave M.E., Goldenberg S.L., Jones E.C., et al. Biochemical and pathological effects of 8 months of neoadjuvant androgen withdrawal therapy before radical prostatectomy in patients with clinically confined prostate cancer. J Urol. 155:1996;213-219.